Tags

Type your tag names separated by a space and hit enter

Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes.
Metabolism. 2003 Feb; 52(2):163-7.M

Abstract

A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nalpha-acetyl-Ndelta-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 +/- 6.1 (mean +/- SD) years and with duration of diabetes of 7.3 +/- 3.1 years, and in 19 nondiabetic controls aged 56.3 +/- 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P =.0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P <.0001), and r = 0.65 for controls (P =.002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and N(epsilon)-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P =.02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A(1c) (HbA(1c)) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds.

Authors+Show Affiliations

Aker Diabetes Research Centre and the Hormone Laboratory, Aker University Hospital, Oslo, Norway.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12601626

Citation

Kilhovd, B K., et al. "Increased Serum Levels of the Specific AGE-compound Methylglyoxal-derived Hydroimidazolone in Patients With Type 2 Diabetes." Metabolism: Clinical and Experimental, vol. 52, no. 2, 2003, pp. 163-7.
Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metab Clin Exp. 2003;52(2):163-7.
Kilhovd, B. K., Giardino, I., Torjesen, P. A., Birkeland, K. I., Berg, T. J., Thornalley, P. J., Brownlee, M., & Hanssen, K. F. (2003). Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 52(2), 163-7.
Kilhovd BK, et al. Increased Serum Levels of the Specific AGE-compound Methylglyoxal-derived Hydroimidazolone in Patients With Type 2 Diabetes. Metab Clin Exp. 2003;52(2):163-7. PubMed PMID: 12601626.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. AU - Kilhovd,B K, AU - Giardino,I, AU - Torjesen,P A, AU - Birkeland,K I, AU - Berg,T J, AU - Thornalley,P J, AU - Brownlee,M, AU - Hanssen,K F, PY - 2003/2/26/pubmed PY - 2003/3/15/medline PY - 2003/2/26/entrez SP - 163 EP - 7 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 52 IS - 2 N2 - A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nalpha-acetyl-Ndelta-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 +/- 6.1 (mean +/- SD) years and with duration of diabetes of 7.3 +/- 3.1 years, and in 19 nondiabetic controls aged 56.3 +/- 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P =.0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P <.0001), and r = 0.65 for controls (P =.002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and N(epsilon)-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P =.02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A(1c) (HbA(1c)) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/12601626/Increased_serum_levels_of_the_specific_AGE_compound_methylglyoxal_derived_hydroimidazolone_in_patients_with_type_2_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026049502052514 DB - PRIME DP - Unbound Medicine ER -